Objective: The objective of this study was todirectly assess the likelihood and timing of alphablocker discontinuation in patients receivingcombination therapy with dutasteride orfinasteride plus an ...

: To evaluate the likelihood of alphaadrenergic antagonist (alpha-blocker) discontinuation in combination with dutasteride or finasteride among patients aged =65 years with enlarged prostate. Methods ...

The Prostate Cancer Prevention Trial has shown a protective effect of finasteride on prostate cancer in low-risk men. It is uncertain whether similar results can be expected when finasteride is used ...

Alpha-adrenoceptor antagonists (alpha-blockers) are widely prescribed to treat lower urinary tract symptoms (LUTS) in men but fail to ameliorate LUTS sufficiently, especially the storage symptoms ...

Rapaflo (silodosin), an alpha blocker marketed by Watson Pharmaceuticals, Inc., in Corona, Calif., for oral, once-daily treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) has ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...